Mr Welten will bring 30 years in finance to Avantium and has extensive experience in the chemical and life-sciences industries. He most recently served as the CFO of Centrient Pharmaceuticals (formerly the joint-venture of DSM and Sinochem) in Singapore. Before he left Centrient, he managed the sale of the company to Bain Capital. Prior to this, Mr Welten held the position of CFO of DSM Resins and DSM Anti-Infectives. He holds a law degree from Leiden University (Netherlands) and an MBA from Boston College (USA).
Edwin Moses (chairman) joined the Supervisory Board of the Company in December 2019.
Edwin Moses is a serial entrepreneur and value creator in European life science companies. He has expertise in high value service provision to the pharmaceutical industry and in drug discovery and development. His primary focus is on high growth businesses and change management. Mr. Moses has 25 years of Board level experience in more than 10 companies, mostly as Chairman.
Edwin Moses is Chairman of the Supervisory Board and member of the Audit Committee.